相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study
Lydia C. T. Buer et al.
JOURNAL OF CROHNS & COLITIS (2017)
Biosimilars in IBD: from theory to practice
Silvio Danese et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
Krisztina B. Gecse et al.
JOURNAL OF CROHNS & COLITIS (2016)
Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations
J. Sieczkowska et al.
JOURNAL OF CROHNS & COLITIS (2016)
Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars
M. Begona Ruiz-Arguello et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis
Klaudia Farkas et al.
JOURNAL OF CROHNS & COLITIS (2016)
Clinical Outcomes Following a Switch from RemicadeA® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study
Lisa J. T. Smits et al.
JOURNAL OF CROHNS & COLITIS (2016)
Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis
Radan Keil et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2016)
Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center
Klaudia Farkas et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events
Reena Khanna et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
Yoon Suk Jung et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea
Sang Hyoung Park et al.
Expert Review of Gastroenterology & Hepatology (2015)
Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study
Jørgen Jahnsen et al.
Expert Review of Gastroenterology & Hepatology (2015)
Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series
Yun-Seong Kang et al.
DIGESTIVE DISEASES AND SCIENCES (2015)
Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?
Howard Lee
AAPS JOURNAL (2014)
Targeting TNF-α for the treatment of inflammatory bowel disease
Thomas Billiet et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study
Kang-Moon Lee et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)
Cost Per Responder Associated with Biologic Therapies for Crohn's Disease, Psoriasis, and Rheumatoid Arthritis
Yifei Liu et al.
ADVANCES IN THERAPY (2012)
Appraisal of the Pediatric Crohn's Disease Activity Index on Four Prospectively Collected Datasets: Recommended Cutoff Values and Clinimetric Properties
Dan Turner et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Meta-analysis of the Efficacy and Safety of Adalimumab, Etanercept, and Infliximab for the Treatment of Rheumatoid Arthritis
Astrid Wiens et al.
PHARMACOTHERAPY (2010)
Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis
Nick Bansback et al.
DERMATOLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Appraisal of the Pediatric Ulcerative Colitis Activity Index (PUCAI)
Dan Turner et al.
INFLAMMATORY BOWEL DISEASES (2009)
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Annabel Kuek et al.
POSTGRADUATE MEDICAL JOURNAL (2007)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Evaluation of the pediatric Crohn disease activity index: A prospective multicenter experience
J Hyams et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Infliximab in inflammatory bowel disease:: clinical outcome in a population based cohort from Stockholm County
T Ljung et al.
GUT (2004)
The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients
JF Colombel et al.
GASTROENTEROLOGY (2004)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
